Market Research Logo

US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)

US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: Insights, Trends and Forecast (2021-2031)

The U.S. OAB market is estimated to reach US$3.49 billion in 2031, growing at a CAGR of 5.01%, for the period spanning from 2021-2031. The factors such as rising ageing population, increasing healthcare expenditure, growing obese population, surging diabetic prevalence, increasing coffee consumption and accelerating economic growth are expected to drive the market growth. However, growth of the industry would be challenged by entry of generic drugs, stringent regulations, associated business risk and side effects of oral therapies. A few notable trends include advancing innovative therapies, rising awareness of overactive bladder, growing adoption of procedural (third line) therapy, development of gene therapy and progressing drug pipeline.

The three main treatment approaches for the treatment of overactive bladder are behavioural therapy (Bladder Training & Pelvic Floor Exercises), prescription therapy (Oral Anticholinergics & β3 Adrenoreceptor Agonist) and procedural therapy (BOTOX & Neuromodulation).

The fastest growing market is the U.S. owing to continuous advancement in β3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs with innovative mechanism of actions drugs.

Scope of the report:

  • The report provides a comprehensive analysis of the U.S. OAB market, segmented on the basis of drug class i.e. Anticholinergics and β3 Adrenoreceptor Agonist and drug type i.e. Vibegron and Mirabegron.
  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players [Allergan Plc, Pfizer Inc., Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Medtronic Plc and Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)] are also presented in detail.
Key Target Audience:
  • Drug Manufacturers
  • Raw Material Suppliers
  • End Users
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities


1. Market Overview
1.1 Overactive Bladder
Table 1: Normal Bladder vs. Overactive Bladder
1.2 Symptoms & Diagnosis
1.3 Treatment
Table 2: OAB Treatment Approaches
1.4 Overactive Bladder with BPH
2. The U.S. Market Analysis
2.1 Overactive Bladder Market
2.1.1 The U.S. Overactive Bladder Market Value Forecast
Table 3: The U.S. Overactive Bladder Market Value Forecast (2021-2031)
2.1.2 The U.S. Overactive Bladder Market Value by Drug Class
Table 4: The U.S. Overactive Bladder Market Value by Drug Class (2021/2031)
2.1.3 The U.S. Anticholinergics Market Value Forecast
Table 5: The U.S. Anticholinergics Market Value Forecast (2021-2031)
2.1.4 The U.S. β3 Adrenoreceptor Agonists Market Value Forecast
Table 6: The U.S. β3 Adrenoreceptor Agonists Market Value Forecast (2021-2031)
2.1.5 The U.S. β3 Adrenoreceptor Agonists Market Value by Drug Type
Table 7: The U.S. β3 Adrenoreceptor Agonists Market Value by Drug Type (2021/2031)
2.1.6 The U.S. Vibegron Drug Revenue Forecast
Table 8: The U.S. Vibegron Drug Revenue Forecast (2021-2031)
2.1.7 The U.S. Overactive Bladder Patient Population Forecast
Table 9: The U.S. Overactive Bladder Patient Population Forecast (2021-2031)
2.1.8 The U.S. Overactive Bladder Treated Patient Population Forecast
Table 10: The U.S. Overactive Bladder Treated Patient Population Forecast (2021-2031)
2.1.9 The U.S. Overactive Bladder Prescriptions Forecast
Table 11: The U.S. Overactive Bladder Prescriptions Forecast (2021-2031)
2.1.10 The U.S. Vibegron Drug Prescriptions Forecast
Table 12: The U.S. Vibegron Drug Prescriptions Forecast (2021-2031)
2.1.11 The U.S. Mirabegron Drug Prescriptions Forecast
Table 13: The U.S. Mirabegron Drug Prescriptions Forecast (2021-2031)
2.2 Overactive Bladder Market with BPH
2.2.1 The U.S. Overactive Bladder with BPH Patient Population Forecast
Table 14: The U.S. Overactive Bladder with BPH Patient Population Forecast (2021-2031)
2.2.2 The U.S. β3 Adrenoreceptor Agonist Market by Penetration Rate
Table 15: The U.S. β3 Adrenoreceptor Agonist Market by Penetration Rate (2021-2031)
2.2.3 The U.S. β3 Adrenoreceptor Agonist Patient Penetration by Drug
Table 16: The U.S. β3 Adrenoreceptor Agonist Patient Penetration by Drug (2021/2025/2031)
2.2.4 The U.S. Vibegron Drug Revenue Forecast
Table 17: The U.S. Vibegron Drug Revenue Forecast (2021-2031)
2.2.5 The U.S. Vibegron Prescriptions Forecast
Table 18: The U.S. Vibegron Prescriptions Forecast (2021-2031)
2.2.6 The U.S. Mirabegron Prescriptions Forecast
Table 19: The U.S. Mirabegron Prescriptions Forecast (2021-2031)
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Rising Ageing Population
Table 20: The U.S. Ageing Population (2014-2018)
3.1.2 Increasing HealthCare Expenditure
Table 21: The U.S. HealthCare Expenditure (1990-2020)
3.1.3 Growing Obese Population
Table 22: The U.S. Obese Population (2014-2018)
3.1.4 Surging Diabetic Prevalence
Table 23: The U.S. Diagnosed Diabetic Population (2014-2018)
3.1.5 Increasing Coffee Consumption
Table 24: The U.S. Coffee Consumption Volume (2014-2018)
3.1.6 Accelerating Economic Growth
Table 25: The U.S. GDP per Capita (2014-2018)
3.2 Key Trends and Developments
3.2.1 Advancing Innovative Therapies
3.2.2 Rising Awareness of Overactive Bladder
3.2.3 Growing Adoption of Procedural (Third Line) Therapy
3.2.4 Development of Gene Therapy
3.2.5 Progressing Drug Pipeline
Table 26: Overactive Bladder Drug Pipeline (2019-2023)
3.3 Challenges
3.3.1 Entry of Generic Drugs
3.3.2 Stringent Regulations
3.3.3 Associated Business Risk
3.3.4 Side Effects of Oral Therapies
4. Competitive Landscape
4.1 Global OAB Market
4.1.1 Key Players – Revenue Comparison
Table 27: Key Players – Revenue Comparison (2018)
4.1.2 Key Players – Market Cap Comparison
Table 28: Key Players – Market Cap Comparison (2019)
4.1.3 Key Players – Research & Development Expenditure Comparison
Table 29: Key Players – Research & Development Expenditure Comparison (2017-2018)
5. Company Profiles
5.1 Allergan Plc
5.1.1 Business Overview
5.1.2 Financial Overview
Table 30: Allergan Net Revenues and Net Loss (2014-2018)
Table 31: Allergan Net Revenues by Segments (2018)
Table 32: Allergan Net Revenues by Region (2018)
5.1.3 Business Strategies
5.2 Pfizer Inc.
5.2.1 Business Overview
Table 33: Pfizer Inc. Segments Overview
5.2.2 Financial Overview
Table 34: Pfizer Revenues and Net Income (2014-2018)
Table 35: Pfizer Revenues by Segments (2018)
Table 36: Pfizer Revenues by Region (2018)
5.2.3 Business Strategies
5.3 Astellas Pharma Inc.
5.3.1 Business Overview
Table 37: Astellas Pharma Segment Overview
5.3.2 Financial Overview
Table 38: Astellas Pharma Revenues and Profit (2015-2019)
Table 39: Astellas Pharma Revenues by Segment (2019)
Table 40: Astellas Pharma Revenues by Region (2019)
5.3.3 Business Strategies
5.4 Hisamitsu Pharmaceutical Co., Inc.
5.4.1 Business Overview
5.4.2 Financial Overview
Table 41: Hisamitsu Pharma Net Sales and Profit (2015-2019)
Table 42: Hisamitsu Pharma Net Sales by Segments (2019)
Table 43: Hisamitsu Pharma Net Sales by Region (2019)
5.4.3 Business Strategies
5.5 Medtronic Plc
5.5.1 Business Overview
Table 44: Medtronic Segment Overview
5.5.2 Financial Overview
Table 45: Medtronic Net Sales and Net Income (2015-2019)
Table 46: Medtronic Net Sales by Segment (2019)
Table 47: Medtronic Net Sales by Region (2019)
5.5.3 Business Strategies
5.6 Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)
5.6.1 Business Overview
Table 48: Sumitomo Chemical (Urovant Sciences) Segment Overview
5.6.2 Financial Overview
Table 49: Sumitomo Chemical (Urovant Sciences) Net Sales and Net Income (2015-2019)
Table 50: Sumitomo Chemical (Urovant Sciences) Net Sales by Segments (2019)
5.6.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report